• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Imperative Care Appoints Shacey Petrovic to Board of Directors

    6/6/23 8:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care
    Get the next $PODD alert in real time by email

    Petrovic brings significant leadership in the global medical technology sector

    Imperative Care, Inc. a medical technology company developing connected innovations to elevate care for people affected by stroke and other ischemic diseases, today announced the appointment of Shacey Petrovic to the company's Board of Directors, effective immediately.

    "We have been intentional in assembling the right balance of investors, executives, and industry experiences, on our board, each with their own unique and complimentary expertise and passion in elevating patient care," said Fred Khosravi, Chairman and CEO of Imperative Care. "Shacey has dedicated her career to improving care for patients while bringing tremendous value to the clinical community. It is a real privilege to have Shacey serve on our board as we benefit from her vast executive experience. We look forward to her meaningful contributions in delivering on our mission to bring more care to more patients."

    Petrovic currently serves on the Board of Insulet Corporation (NASDAQ:PODD), a medical device company in the diabetes space that developed a wearable, automated product that has transformed how insulin is delivered. Previously, Petrovic was CEO of Insulet from 2019 to 2022, after serving in several other executive roles at the company. Under her leadership, the company grew from $2 billion in market cap to over $20 billion.

    "I am honored to join the Imperative Care board at this exciting time in the company's history," said Petrovic. "While many companies claim to put the patient first, Imperative Care has truly built its business around the specific needs of patients affected by stroke and vascular diseases. The company's commitment to patients is palpable in its leadership and people, and evident in its impact-focused innovations that expand and connect care for patients."

    Petrovic also served as President and Chief Executive Officer of Clinical Innovations, LLC, a developer and manufacturer of medical devices and diagnostics for women's health. From 2000 to 2013, she served in a number of key roles at Hologic, Inc. and Cytyc Corporation, which merged with Hologic in October 2007, including Vice President and General Manager of Hologic's GYN Surgical Products division, as well as various sales and marketing leadership roles in the U.S. and Europe.

    Petrovic earned her Bachelor of Science in Biology from the University of Wisconsin. She also currently serves on the Board of Directors for Exact Sciences and Ambu A/S.

    "We are thrilled to have Shacey join our board," said John Hamre, Ph.D., Chairman of Imperative Care's Nominating and Governance Committee. "She brings a wealth of insight that will further strengthen Imperative Care's work to elevate patient care and make our innovations available more broadly."

    About Imperative Care, Inc.

    Imperative Care is a commercial-stage medical technology company researching and developing connected innovations to elevate care for people affected by devastating vascular diseases such as stroke and pulmonary embolism. The company has four businesses focused on addressing specific gaps in treatment and care to make an impact across the entire patient journey. Imperative Care is based in Campbell, Calif. https://imperativecare.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230606005341/en/

    Get the next $PODD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PODD

    DatePrice TargetRatingAnalyst
    6/16/2025$365.00Buy
    Truist
    5/30/2025$380.00Buy
    Goldman
    5/13/2025$350.00Peer Perform → Outperform
    Wolfe Research
    4/29/2025Outperform → Peer Perform
    Wolfe Research
    3/6/2025$340.00Outperform
    RBC Capital Mkts
    11/6/2024$300.00Outperform
    Bernstein
    5/30/2024$235.00Buy
    Redburn Atlantic
    5/7/2024$200.00Peer Perform → Outperform
    Wolfe Research
    More analyst ratings

    $PODD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Global Operations Singh Prem exercised 1,343 shares at a strike of $271.28 and sold $429,760 worth of shares (1,343 units at $320.00) (SEC Form 4)

    4 - INSULET CORP (0001145197) (Issuer)

    8/8/25 4:03:57 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    SVP, Chief HR Officer Davis Lisa Blair was granted 2,477 shares (SEC Form 4)

    4 - INSULET CORP (0001145197) (Issuer)

    8/5/25 4:09:50 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    New insider Davis Lisa Blair claimed no ownership of stock in the company (SEC Form 3)

    3 - INSULET CORP (0001145197) (Issuer)

    7/29/25 4:15:31 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $PODD
    SEC Filings

    View All

    SEC Form 10-Q filed by Insulet Corporation

    10-Q - INSULET CORP (0001145197) (Filer)

    8/7/25 4:04:35 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - INSULET CORP (0001145197) (Filer)

    8/7/25 7:03:53 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation

    8-K - INSULET CORP (0001145197) (Filer)

    6/9/25 4:47:07 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $PODD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Insulet to Participate in Upcoming Investor Conferences

    Insulet Corporation (NASDAQ:PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the upcoming investor conferences (all Eastern Time): Wells Fargo 2025 Healthcare Conference in Boston on September 4 at 3:00 p.m. Baird 2025 Global Healthcare Conference in New York City on September 9 at 12:15 p.m. Bernstein Insights: Healthcare Leaders & Disruptors Forum in New York City on September 24 at 9:40 a.m. The live audio webcast and replay of the presentations will be accessible on the Insulet Investor Relations website: investors.insulet.com/events. About Insulet Corporation: Insulet Corporat

    8/19/25 6:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet Reports Second Quarter 2025 Revenue Increase of 32.9% Year-Over-Year (31.3% Constant Currency1)

    Raising Full Year Revenue and Adjusted Operating Margin Guidance Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended June 30, 2025. Second Quarter Financial Highlights: Revenue of $649.1 million, up 32.9%, or 31.3% in constant currency, exceeds the high end of the Company's guidance range of 26.0% in constant currency Total Omnipod revenue of $639.0 million, up 33.0%, or 31.4% in constant currency U.S. Omnipod revenue of $453.2 million, up 28.7% International Omnipod revenue of $185.8 million, up 45.0%, or 38.8% in cons

    8/7/25 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet to Announce Second Quarter 2025 Financial Results on August 7, 2025

    Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the second quarter of 2025 on August 7, 2025, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time). The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, "Events and Presentations," and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or (929) 203-2

    7/8/25 6:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $PODD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist initiated coverage on Insulet with a new price target

    Truist initiated coverage of Insulet with a rating of Buy and set a new price target of $365.00

    6/16/25 7:50:27 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Goldman initiated coverage on Insulet with a new price target

    Goldman initiated coverage of Insulet with a rating of Buy and set a new price target of $380.00

    5/30/25 8:41:35 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet upgraded by Wolfe Research with a new price target

    Wolfe Research upgraded Insulet from Peer Perform to Outperform and set a new price target of $350.00

    5/13/25 8:51:02 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $PODD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, CFO & Treasurer Chadwick Ana Maria bought $20,600 worth of shares (100 units at $206.00), increasing direct ownership by 0.76% to 13,314 units (SEC Form 4)

    4 - INSULET CORP (0001145197) (Issuer)

    8/29/24 4:17:26 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    SEC Form 4: Singh Prem bought $169 worth of shares (1 units at $168.92), increasing direct ownership by 0.02% to 4,032 units

    4 - INSULET CORP (0001145197) (Issuer)

    9/21/23 4:48:23 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $PODD
    Leadership Updates

    Live Leadership Updates

    View All

    Insulet Appoints Ashley McEvoy President and CEO

    Expects to Exceed First Quarter Revenue Guidance and Raise Full Year 2025 Guidance Insulet Corporation (NASDAQ:PODD) ("Insulet" or the "Company"), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its Board of Directors has appointed Ashley McEvoy President and Chief Executive Officer and a member of the Board of Directors, effective immediately. Ms. McEvoy succeeds Jim Hollingshead, who has agreed with Insulet's Board of Directors that his employment with the Company will cease effective as of April 28, 2025, and resigned from the Insulet Board of Directors. The Insulet Board and Mr. Hollingshead mutually agreed that now is the rig

    4/28/25 6:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet to Host Investor Day on June 5, 2025

    Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, will host an Investor Day at the Company's global headquarters in Acton, Massachusetts on Thursday, June 5, 2025. Presentations will be led by Jim Hollingshead, President and CEO, members of the Executive Leadership Team, and independent experts. The agenda will include a comprehensive overview of the Company's leading Omnipod® 5 platform, strategic priorities, market opportunities, growth drivers, innovation roadmap, and financial outlook. Presentations will begin at 10:00 a.m. (ET) and conclude at approximately 1:30 p.m. (ET). The Company

    3/11/25 6:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Biote Announces CEO Retirement and Succession Plan

    Terry Weber Retiring as CEO and Director and Transitioning to Strategic Advisor to Company's Board of Directors Health Care Veteran Bret Christensen to Succeed Terry Weber as CEO and Director biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Terry Weber is retiring as Chief Executive Officer and stepping down from the Company's Board of Directors, effective as of February 1, 2025. She will be transitioning to Strategic Advisor to the Company's Board of Directors. Concurrently, Mr. Bret Christensen has been named Chief Executi

    1/30/25 4:10:00 PM ET
    $BTMD
    $HOLX
    $MYGN
    Medicinal Chemicals and Botanical Products
    Health Care
    Medical Electronics
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    $PODD
    Financials

    Live finance-specific insights

    View All

    Insulet Reports Second Quarter 2025 Revenue Increase of 32.9% Year-Over-Year (31.3% Constant Currency1)

    Raising Full Year Revenue and Adjusted Operating Margin Guidance Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended June 30, 2025. Second Quarter Financial Highlights: Revenue of $649.1 million, up 32.9%, or 31.3% in constant currency, exceeds the high end of the Company's guidance range of 26.0% in constant currency Total Omnipod revenue of $639.0 million, up 33.0%, or 31.4% in constant currency U.S. Omnipod revenue of $453.2 million, up 28.7% International Omnipod revenue of $185.8 million, up 45.0%, or 38.8% in cons

    8/7/25 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet to Announce Second Quarter 2025 Financial Results on August 7, 2025

    Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the second quarter of 2025 on August 7, 2025, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time). The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, "Events and Presentations," and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or (929) 203-2

    7/8/25 6:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet Reports First Quarter 2025 Revenue Increase of 29% Year-Over-Year (30% Constant Currency1)

    Raising Full Year Revenue and Gross Margin Guidance Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended March 31, 2025. "Our first quarter results showcase the strong execution and dedication of the Insulet team, who has continued to expand the reach of Omnipod 5 technology to people living with diabetes globally. As Insulet's new President and CEO, I see a path to scale the Company from an emerging diabetes leader to a durable growth engine, driving an even greater impact for our partners, stakeholders, and most importantly, our P

    5/8/25 4:01:00 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $PODD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Insulet Corporation

    SC 13G/A - INSULET CORP (0001145197) (Subject)

    11/12/24 12:53:28 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Insulet Corporation

    SC 13G/A - INSULET CORP (0001145197) (Subject)

    10/7/24 11:37:08 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Insulet Corporation (Amendment)

    SC 13G/A - INSULET CORP (0001145197) (Subject)

    2/13/24 5:06:23 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care